V C Jordan

Author PubWeight™ 248.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999 7.30
2 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992 3.54
3 A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977 3.03
4 The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984 3.02
5 Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998 2.88
6 A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 1993 2.65
7 Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998 2.50
8 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001 2.26
9 Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 1992 2.19
10 MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997 2.12
11 Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991 2.04
12 Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990 1.97
13 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988 1.80
14 Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996 1.79
15 Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 1990 1.78
16 Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984 1.74
17 Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000 1.73
18 Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep 1976 1.63
19 Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991 1.55
20 Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J Biol Chem 1994 1.53
21 Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987 1.52
22 Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976 1.50
23 Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 1982 1.48
24 Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988 1.44
25 Tamoxifen and contralateral breast cancer. J Am Coll Surg 1999 1.41
26 An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 1992 1.39
27 Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol 1987 1.38
28 Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 1981 1.37
29 A risk-benefit assessment of tamoxifen therapy. Drug Saf 1993 1.34
30 Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005 1.31
31 Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988 1.29
32 Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol 1976 1.27
33 Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980 1.27
34 An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res 1995 1.23
35 High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol 1989 1.21
36 Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988 1.19
37 Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 1988 1.19
38 Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat. Mol Cell Endocrinol 1977 1.18
39 Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989 1.17
40 Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol 1980 1.16
41 Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995 1.16
42 Structure-activity relationships of estrogens. Environ Health Perspect 1985 1.15
43 Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat 1987 1.13
44 Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 1976 1.12
45 Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer 1996 1.12
46 Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 1975 1.06
47 Reliability of steroid hormone receptor assays: an international study. Eur J Cancer Clin Oncol 1983 1.06
48 Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol 1990 1.05
49 High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992 1.04
50 Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol Cell Endocrinol 1977 1.03
51 Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000 1.03
52 Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc 1987 1.02
53 Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 2001 1.02
54 Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 1987 1.02
55 Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res 1990 1.01
56 Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 2012 1.01
57 A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996 1.00
58 Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 1990 0.99
59 Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. Br J Pharmacol 2013 0.99
60 The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 1994 0.98
61 Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994 0.98
62 The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat [proceedings]. Br J Pharmacol 1978 0.97
63 Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat 1994 0.96
64 Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987 0.96
65 Estrogenic activity of phenol red. Mol Cell Endocrinol 1988 0.96
66 Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 1997 0.96
67 Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 2000 0.95
68 Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 1998 0.95
69 Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 1983 0.95
70 Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. Mol Pharmacol 1984 0.95
71 Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 1983 0.94
72 A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res 1996 0.94
73 Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer 2003 0.94
74 Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 1989 0.94
75 The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 1998 0.93
76 Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res 1984 0.93
77 Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993 0.93
78 How safe is tamoxifen? BMJ 1993 0.93
79 Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol Oncol 2001 0.92
80 Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 1989 0.91
81 The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 1998 0.91
82 Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth. Cancer Res 1989 0.90
83 Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000 0.90
84 A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 1997 0.90
85 Estrogenic effects of phenolphthalein on human breast cancer cells in vitro. Breast Cancer Res Treat 1987 0.90
86 Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice. Cancer Res 1989 0.89
87 Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 2002 0.89
88 Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 1989 0.89
89 Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. Mol Pharmacol 1984 0.89
90 Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 1995 0.89
91 Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 2004 0.89
92 Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993 0.88
93 An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem 1983 0.88
94 Designer estrogens. Sci Am 1998 0.88
95 Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 2001 0.88
96 Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health 1978 0.87
97 Tamoxifen and endometrial cancer. Lancet 1988 0.87
98 Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. Eur J Cancer Clin Oncol 1989 0.87
99 Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J Steroid Biochem Mol Biol 2001 0.87
100 Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen. Cancer Res 1989 0.87
101 Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. J Biol Chem 1983 0.86
102 Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch Surg 1993 0.86
103 Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. Br J Cancer 1998 0.86
104 Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss. Eur J Cancer 1994 0.86
105 Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anticancer Drugs 1995 0.86
106 Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin. J Endocrinol 1976 0.86
107 Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990 0.86
108 Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen. Endocrinology 1980 0.86
109 Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro. Br J Pharmacol 1986 0.85
110 Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999 0.85
111 Interaction of [3H] estradiol - and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Res Treat 1983 0.85
112 A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol 1995 0.85
113 Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 1997 0.85
114 Metabolism of steroid-modifying anticancer agents. Pharmacol Ther 1988 0.85
115 Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. Clin Cancer Res 2001 0.85
116 Considerations into the mechanism of estrogen-stimulated uterine prostaglandin synthesis. Prostaglandins 1976 0.84
117 Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992 0.84
118 Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology 1981 0.84
119 Clinical potential of new antiestrogens. J Clin Oncol 1997 0.84
120 The effect of estrogen and progesterone on uterine prostaglandin biosynthesis in the ovariectomized rat. Biol Reprod 1975 0.84
121 Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. Br J Cancer 2002 0.84
122 In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo. Cancer Res 1988 0.84
123 Comparative antioestrogen action in experimental breast cancer. Adv Exp Med Biol 1981 0.84
124 William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res Treat 1993 0.84
125 Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharmacol 1985 0.84
126 The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol 1997 0.84
127 Growth stimulation and differential regulation of transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, and TGF beta 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells. Mol Endocrinol 1991 0.84
128 Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett 1994 0.83
129 Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation. Br J Urol 1988 0.83
130 Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999 0.83
131 Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 1992 0.83
132 Effect of non-steroidal anti-oestrogens on the concentration of rat uterine progesterone receptors. J Endocrinol 1978 0.83
133 Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 1993 0.83
134 In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. Eur J Endocrinol 2000 0.83
135 Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999 0.82
136 Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. Eur J Cancer Clin Oncol 1989 0.82
137 Rat uterine growth and induction of progesterone receptor without estrogen receptor translocation. Endocrinology 1985 0.82
138 Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med 1987 0.82
139 Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer 1991 0.82
140 Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 1983 0.82
141 Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 1995 0.82
142 Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 1993 0.82
143 Prophylactic tamoxifen. Lancet 1986 0.82
144 Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000 0.82
145 Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol 1987 0.81
146 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 1994 0.81
147 Effects of tamoxifen in relation to breast cancer. Br Med J 1977 0.81
148 Targeted anti-estrogens to treat and prevent diseases in women. Mol Med Today 1996 0.81
149 Dose-related effects of non-steroidal antioestrogens nad oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J Endocrinol 1978 0.81
150 How is tamoxifen's action subverted? J Natl Cancer Inst 2000 0.81
151 Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. Clin Cancer Res 2001 0.81
152 Novel agents to modulate oestrogen action. Br Med Bull 2000 0.81
153 Estrogen receptor distribution in enucleated breast cancer cell lines. Endocrinology 1988 0.81
154 EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway. Mol Cell Endocrinol 2000 0.81
155 The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res 1999 0.81
156 Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer. BMJ 1999 0.81
157 Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993 0.81
158 What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 1994 0.80
159 Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. J Natl Cancer Inst 2001 0.80
160 Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Cancer Res 1996 0.80
161 Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res 1995 0.80
162 Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation. J Chromatogr 1983 0.80
163 Subcellular compartmentalization of MCF-7 estrogen receptor synthesis and degradation. Mol Cell Endocrinol 1993 0.80
164 Anti-oestrogenic activity in compounds related to ethamoxytriphetol (MER 25), clomiphene and MRL 37. Br J Pharmacol 1973 0.80
165 Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol. Br J Pharmacol 2014 0.80
166 Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res 1997 0.80
167 Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus. Mol Cell Endocrinol 1982 0.80
168 Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes. J Med Chem 1988 0.80
169 Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Mol Pharmacol 1991 0.80
170 Steroid hormone receptors in adenocarcinoma of the endometrium. Gynecol Oncol 1980 0.80
171 Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus. Endocrinology 1985 0.80
172 Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. Br J Cancer 1998 0.80
173 Effect of oestradiol benzoate, tamoxifen and monohydroxytamoxifen on immature rat uterine progesterone receptor synthesis and endometrial cell division. J Steroid Biochem 1979 0.80
174 Tamoxifen and tumorigenicity: a predictable concern. J Natl Cancer Inst 1995 0.79
175 A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer. Int J Oncol 2000 0.79
176 The effect of reported prostaglandin synthetase inhibitors on estradiol-stimulated uterine prostaglandin biosynthesis in vivo in the ovariectomized rat. Prostaglandins 1976 0.79
177 Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst 1990 0.79
178 Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. J Steroid Biochem 1983 0.79
179 Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. Cancer 1993 0.79
180 Tamoxifen: too much of a good thing? J Clin Oncol 1999 0.79
181 Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line. Br J Cancer 1997 0.79
182 Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann Oncol 1998 0.79
183 Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995 0.79
184 The binding of [3H]-oestradiol-17 beta in the immature rat uterus during the sequential administration of non-steroidal anti-oestrogens. Br J Pharmacol 1979 0.79
185 The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot). Int J Radiat Oncol Biol Phys 1995 0.79
186 The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis. Carcinogenesis 1996 0.79
187 Mutations of the estrogen receptor in endometrial carcinoma: evidence of an association with high tumor grade. Gynecol Oncol 1996 0.79
188 Risk factors and the prevention of breast cancer with tamoxifen. Cancer Surv 1993 0.79
189 The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. Eur J Cancer Clin Oncol 1989 0.78
190 Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res Treat 1990 0.78
191 Long-term adjuvant tamoxifen study: clinical update. Breast Cancer Res Treat 1987 0.78
192 Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Lett 1998 0.78
193 Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 1984 0.78
194 Pure antiestrogens as a new therapy for breast cancer. Oncol Res 1997 0.78
195 High affinity binding of anti-oestrogen to the chick liver nuclear oestrogen receptor. Biochem J 1982 0.78
196 Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice. Cancer Lett 2000 0.78
197 Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry. Cancer Res 1993 0.78
198 The mode of action of the antitumour agent GP 48,989 in the rat. Eur J Cancer 1979 0.78
199 Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2. Breast Cancer Res Treat 1990 0.78
200 Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 2006 0.78
201 Targeted antiestrogens for the prevention of breast cancer. Oncol Res 1999 0.78
202 Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosis. J Endocrinol 1980 0.78
203 Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 1992 0.78
204 The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells. Cancer Lett 1995 0.78
205 A comparative study of electrophoretic mobilities of [3H]-estradiol and monohydroxytamoxifen binding components in the cytosols of human breast carcinomas and sera of healthy adult females. Eur J Cancer Clin Oncol 1983 0.78
206 Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. Biochem Pharmacol 1985 0.78
207 Tamoxifen to raloxifene and beyond. Semin Oncol 2001 0.78
208 Hormonal therapy for breast cancer. An update. Hematol Oncol Clin North Am 1999 0.78
209 Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. J Immunother (1991) 1992 0.77
210 Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse. J Reprod Fertil 1975 0.77
211 Inhibition of cell division and stimulation of progesterone receptor synthesis in rat oestrogen target tissues by non-steroidal antioestrogens. Adv Exp Med Biol 1979 0.77
212 Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies. Horm Res 2000 0.77
213 Chemotherapy is antihormonal therapy--how much proof do oncologists need? Eur J Cancer 1998 0.77
214 Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations. J Steroid Biochem Mol Biol 1998 0.77
215 Contrasting subcellular responses to monohydroxytamoxifen and oestradiol benzoate in the immature rat uterus [proceedings]. Br J Pharmacol 1978 0.77
216 Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy. Biochem Pharmacol 1983 0.77
217 Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 1987 0.77
218 Sensitivity and insensitivity of breast cancer to tamoxifen. J Steroid Biochem Mol Biol 1990 0.77
219 Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995 0.77
220 Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 1994 0.77
221 The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. J Mammary Gland Biol Neoplasia 1999 0.77
222 Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol 1988 0.77
223 Control of experimental breast cancer by antioestrogenic therapies [proceedings]. Br J Clin Pharmacol 1979 0.77
224 A comparison, at the cellular and subcellular levels, of the effects of tamoxifen and oestradiol benzoate on the immature rat uterus [proceedings]. Br J Pharmacol 1978 0.77
225 Tamoxifen and endometrial cancer. Lancet 1989 0.76
226 Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States. Cancer Res 1986 0.76
227 Tamoxifen to prevent breast cancer. Adv Surg 2000 0.76
228 Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 2001 0.76
229 Inhibition of oestrogen-stimulated prolactin release by anti-oestrogens. J Endocrinol 1975 0.76
230 Tamoxifen for the prevention of breast cancer in the high-risk woman. Ann Surg Oncol 2000 0.76
231 Risks and benefits of tamoxifen therapy. Oncology (Williston Park) 1997 0.76
232 Anti-oestrogen action in experimental breast cancer. Recent Results Cancer Res 1980 0.76
233 Binding of [3H]monohydroxytamoxifen by immature rat tissues in vivo. Endocrinology 1982 0.76
234 Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes. J Endocrinol 1975 0.76
235 Reduced antioestrogenic activity in derivatives of tamoxifen unable to undergo metabolic p-hydroxylation [proceedings]. Br J Pharmacol 1980 0.75
236 Nuclear [3H]4-hydroxytamoxifen (4-OHTAM)- and [3H]estradiol (E2)-estrogen receptor complexes in the MCF-7 breast cancer and GH3 pituitary tumor cell lines. Mol Cell Endocrinol 1984 0.75
237 A therapeutic withdrawal can make a strategic advance. Ann Oncol 1992 0.75
238 Modulation of nuclear oestrogen receptor levels by oestrogen and antioestrogen [proceedings]. Br J Pharmacol 1980 0.75
239 Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens. Eur J Cancer 1981 0.75
240 Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis 1996 0.75
241 Safety of tamoxifen. BMJ 1994 0.75
242 Oestrogenic, anti-oestrogenic and fertility effects of some triphenylethanes and triphenylethylenes related to ethamoxytriphetol (MER 25). Br J Pharmacol 1976 0.75
243 The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohydroxytamoxifen is associated with changes in the properties of the estrogen receptor. J Steroid Biochem 1984 0.75
244 Antiestrogens and the reduction in circulating cholesterol. J Clin Oncol 1996 0.75
245 Antioestrogenic derivatives of nafoxidine stimulate progesterone receptor synthesis in vivo [proceedings]. Br J Pharmacol 1980 0.75
246 Control of experimental breast cancer by antioestrogenic therapies [proceedings]. Br J Pharmacol 1979 0.75
247 Targeting antihormone resistance in breast cancer: a simple solution. Ann Oncol 2003 0.75
248 After the menopause: tamoxifen and other new prevention maintenance therapies. J Womens Health 1997 0.75
249 Raloxifene for the treatment and prevention of breast cancer? Expert Rev Anticancer Ther 2001 0.75
250 Inhibition of oestradiol binding to oestrogen receptor proteins by a methyl-substituted analogue of tamoxifen. J Endocrinol 1976 0.75
251 A molecular strategy to control tamoxifen resistant breast cancer. Cancer Surv 1992 0.75
252 Tamoxifen prophylaxis. Lancet 1986 0.75
253 The forgotten group at risk for breast cancer. J Clin Oncol 1990 0.75
254 Binding of [3H] monohydroxytamoxifen in ovarian carcinoma. Br J Obstet Gynaecol 1983 0.75
255 Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2016 0.75
256 Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas. Eur J Cancer Clin Oncol 1981 0.75
257 Antiestrogen therapy for breast cancer: current strategies and future prospects. Cancer Treat Res 1988 0.75
258 Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats. Toxicol Sci 1998 0.75
259 Hormonal treatment of advanced breast cancer. Surg Oncol Clin N Am 1995 0.75
260 An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor. J Steroid Biochem Mol Biol 1996 0.75
261 Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res Treat 1993 0.75
262 Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle. J Endocrinol 1975 0.75
263 Chemoprevention of breast cancer. Cancer Treat Res 2001 0.75
264 The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model. Breast Cancer Res Treat 1993 0.75
265 Antiestrogenic effect of trifluoperazine in mice. Biochem Pharmacol 1985 0.75
266 Health and safety inspections. Lancet 1977 0.75
267 [Effect of tamoxifen on estrogen-stimulated growth of MCF-7 tumors in athymic mice: preliminary report]. Nihon Geka Gakkai Zasshi 1990 0.75
268 Current controversies in breast cancer management. Curr Probl Surg 1999 0.75
269 Binding of [3H] monohydroxytamoxifen in human breast carcinoma cytosols. Eur J Cancer 1981 0.75
270 Design of an ideal hormone replacement therapy for women. Mol Carcinog 1996 0.75
271 Steroid and prostaglandin relations during the menstrual cycle. Obstet Gynecol 1977 0.75
272 Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat. Life Sci 1988 0.75
273 A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens. Breast Cancer Res Treat 1993 0.75
274 Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy. Breast Cancer 1998 0.75
275 Long-term tamoxifen therapy for breast cancer. Important Adv Oncol 1989 0.75
276 Effects of antiestrogens on the induction of vitellogenin and its mRNA in Xenopus laevis. J Steroid Biochem 1986 0.75
277 Structural components necessary for the antiestrogenic activity of tamoxifen. J Steroid Biochem 1989 0.75
278 The evolving role of endocrine therapy for treatment and prevention of breast cancer. Cancer Chemother Biol Response Modif 2001 0.75
279 An immobilized antiestrogen binds a specific uterine protein in addition to estrogen receptor proteins. Mol Cell Endocrinol 1984 0.75
280 Targeted antiestrogens. Prog Clin Biol Res 1997 0.75
281 Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat 1994 0.75
282 Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case. Surg Today 2001 0.75
283 Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor. Int J Oncol 1998 0.75
284 Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? Semin Surg Oncol 1997 0.75
285 Tamoxifen and endometrial cancer: from experiment to patient. Recent Results Cancer Res 1996 0.75
286 Meeting report: long-term antihormonal therapy for breast cancer. Eur J Cancer 1991 0.75
287 Antiestrogen therapy for breast cancer: current strategies and potential causes for therapeutic failure. Cancer Treat Res 1991 0.75
288 Adjuvant antiestrogen therapy for breast cancer. Past, present, and future. Surg Clin North Am 1990 0.75
289 Effect of submandibular gland removal on carcinogen induced rat mammary tumors. Eur J Cancer Clin Oncol 1987 0.75
290 The duration of adjuvant tamoxifen therapy. Cancer Treat Res 1998 0.75
291 Antiestrogens: the past and the future. Zentralbl Gynakol 2002 0.75
292 Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer. Endocr Relat Cancer 1999 0.75
293 Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death. Br J Cancer 2016 0.75
294 Legislation and hospitals. Occup Health (Lond) 1971 0.75
295 The biological significance of the interaction of estrogen agonists and antagonists with the estrogen receptor. Receptor 1993 0.75
296 New strategies for the treatment of breast cancer. Breast Cancer 2001 0.75
297 Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression. Biochem Pharmacol 1998 0.75
298 Relation of steroids and prostaglandin at vaginal delivery and cesarean section. Obstet Gynecol 1975 0.75